Physician profile
Praneetha Musty
NPI 1306191820
$11,485.71
in general payments reported to CMS, 2019-2025
39 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $1,024 · 2021: $2,351 · 2022: $3,298 · 2023: $1,534 · 2024: $695 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.76 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,510.38 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,270.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,055.34 | 2019-2025 | |
| Pfizer INC. | $1,015.20 | 2019-2025 | |
| Janssen Biotech, INC. | $839.91 | 2019-2025 | Tremfya |
| Ucb, INC. | $678.83 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $673.11 | 2019-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $559.05 | 2019-2024 | Actemra |
| Lilly USA, LLC | $511.65 | 2019-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $368.51 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $351.80 | 2019-2023 | Krystexxa |
| Cumberland Pharmaceuticals, INC. | $332.58 | 2021-2023 | Kristalose |
| Astrazeneca Pharmaceuticals LP | $194.30 | 2022-2025 | Saphnelo, Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.52 | 2020-2024 | Ofev |
| Regeneron Healthcare Solutions, INC. | $134.13 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praneetha Musty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.